Therapeutic potential of anti-angiogenic multitarget N,O-Sulfated E. Coli K5 Polysaccharide in diabetic retinopathy

Diabetes

Volumn 64, Issue 7, 2015, Pages 2581-2592

  Rezzola, Sara ^a   Dal Monte, Massimo ^b   Belleri, Mirella ^a   Bugatti, Antonella ^a   Chiodelli, Paola ^a   Corsini, Michela ^a   Cammalleri, Maurizio ^b   Cancarini, Anna ^a   Morbidelli, Lucia ^c   Oreste, Pasqua ^d   Bagnoli, Paola ^b   Semeraro, Francesco ^a   Presta, Marco ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

^d Glycores 2000 ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BACTERIAL POLYSACCHARIDE; BACTERIAL POLYSACCHARIDE K5; GLYCOSAMINOGLYCAN POLYSULFATE; PROTEOHEPARAN SULFATE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 2; CAPSULAR POLYSACCHARIDE K5; HEPARIN;

ADULT; AGED; ANGIOGENESIS; ANGIOGENESIS ASSAY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL ADHESION; COMPLEX FORMATION; CONTROLLED STUDY; DIABETIC RETINOPATHY; EMBRYO; ESCHERICHIA COLI; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETINA NEOVASCULARIZATION; UPREGULATION; VASCULAR RING; VITREOUS BODY; ANIMAL; ANTAGONISTS AND INHIBITORS; BACTERIAL CAPSULE; C57BL MOUSE; CHICK EMBRYO; CHO CELL LINE; CRICETULUS; DRUG EFFECTS; METABOLISM; RETINAL NEOVASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; BACTERIAL CAPSULES; CHICK EMBRYO; CHO CELLS; CRICETULUS; DIABETIC RETINOPATHY; HEPARIN; HUMANS; MICE; MICE, INBRED C57BL; RETINAL NEOVASCULARIZATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VITREOUS BODY;

EID: 84928608876     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db14-1378     Document Type: Article

References (48)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27: 1047-1053
2. Gariano RF, Gardner TW. Retinal angiogenesis in development and disease. Nature 2005;438:960-966
3. Simó R, Carrasco E, García-Ramírez M, Hernández C. Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Curr Diabetes Rev 2006; 2:71-98
4. Sherris D. Ocular drug development-future directions. Angiogenesis 2007; 10:71-76
5. Wang S, Park JK, Duh EJ. Novel targets against retinal angiogenesis in diabetic retinopathy. Curr Diab Rep 2012;12:355-363
6. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-1487
7. Tang J, Kern TS. Inflammation in diabetic retinopathy. Prog Retin Eye Res 2011;30:343-358
8. Mathews MK, Merges C, McLeod DS, Lutty GA. Vascular endothelial growth factor and vascular permeability changes in human diabetic retinopathy. Invest Ophthalmol Vis Sci 1997;38:2729-2741
9. Adamis AP, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina 2005;25:111-118
10. Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, Hartnett ME. Vascular endothelial growth factor in eye disease. Prog Retin Eye Res 2008;27: 331-371
11. Nicholson BP, Schachat AP. A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2010;248:915-930
12. Boyer DS, Hopkins JJ, Sorof J, Ehrlich JS. Anti-vascular endothelial growth factor therapy for diabetic macular edema. Ther Adv Endocrinol Metab 2013;4: 151-169
13. Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: A review of literature. Eye (Lond) 2013;27:787-794
14. Cheung N, Wong IY, Wong TY. Ocular anti-VEGF therapy for diabetic retinopathy: Overview of clinical efficacy and evolving applications. Diabetes Care 2014;37:900-905
15. Chen Y, Hu Y, Lin M, et al. Therapeutic effects of PPARa agonists on diabetic retinopathy in type 1 diabetes models. Diabetes 2013;62:261-272
16. Lee K, Hu Y, Ding L, et al. Therapeutic potential of a monoclonal antibody blocking the Wnt pathway in diabetic retinopathy. Diabetes 2012;61:2948-2957
17. Rusnati M, Presta M. Interaction of angiogenic basic fibroblast growth factor with endothelial cell heparan sulfate proteoglycans. Biological implications in neovascularization. Int J Clin Lab Res 1996;26:15-23
18. Grünewald FS, Prota AE, Giese A, Ballmer-Hofer K. Structure-function analysis of VEGF receptor activation and the role of coreceptors in angiogenic signaling. Biochim Biophys Acta 2010;1804:567-580
19. Presta M, Leali D, Stabile H, et al. Heparin derivatives as angiogenesis inhibitors. Curr Pharm Des 2003;9:553-566
20. Lange C, Ehlken C, Martin G, et al. Intravitreal injection of the heparin analog 5-amino-2-naphthalenesulfonate reduces retinal neovascularization in mice. Exp Eye Res 2007;85:323-327
21. Nishiguchi KM, Kataoka K, Kachi S, Komeima K, Terasaki H. Regulation of pathologic retinal angiogenesis in mice and inhibition of VEGF-VEGFR2 binding by soluble heparan sulfate. PLoS ONE 2010;5:e13493
22. Smith LE, Wesolowski E, McLellan A, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 1994;35:101-111
23. Stahl A, Connor KM, Sapieha P, et al. The mouse retina as an angiogenesis model. Invest Ophthalmol Vis Sci 2010;51:2813-2826
24. Zhang D, Kaufman PL, Gao G, Saunders RA, Ma JX. Intravitreal injection of plasminogen kringle 5, an endogenous angiogenic inhibitor, arrests retinal neovascularization in rats. Diabetologia 2001;44:757-765
25. Vann WF, Schmidt MA, Jann B, Jann K. The structure of the capsular polysaccharide (K5 antigen) of urinary-tract-infective Escherichia coli 010:K5:H4. A polymer similar to desulfo-heparin. Eur J Biochem 1981;116:359-364
26. Rusnati M, Oreste P, Zoppetti G, Presta M. Biotechnological engineering of heparin/heparan sulphate: A novel area of multi-target drug discovery. Curr Pharm Des 2005;11:2489-2499
27. Rusnati M, Urbinati C. Polysulfated/sulfonated compounds for the development of drugs at the crossroad of viral infection and oncogenesis. Curr Pharm Des 2009;15:2946-2957
28. Leali D, Belleri M, Urbinati C, et al. Fibroblast growth factor-2 antagonist activity and angiostatic capacity of sulfated Escherichia coli K5 polysaccharide derivatives. J Biol Chem 2001;276:37900-37908
29. Bugatti A, Giagulli C, Urbinati C, et al. Molecular interaction studies of HIV-1 matrix protein p17 and heparin: Identification of the heparin-binding motif of p17 as a target for the development of multitarget antagonists. J Biol Chem 2013; 288:1150-1161
30. Mitola S, Moroni E, Ravelli C, Andres G, Belleri M, Presta M. Angiopoietin-1 mediates the proangiogenic activity of the bone morphogenic protein antagonist Drm. Blood 2008;112:1154-1157
31. Ronca R, Benzoni P, Leali D, et al. Antiangiogenic activity of a neutralizing human single-chain antibody fragment against fibroblast growth factor receptor 1. Mol Cancer Ther 2010;9:3244-3253
32. Rezzola S, Belleri M, Gariano G, et al. In vitro and ex vivo retina angiogenesis assays. Angiogenesis 2014;17:429-442
33. Rezzola S, Belleri M, Ribatti D, Costagliola C, Presta M, Semeraro F. A novel ex vivo murine retina angiogenesis (EMRA) assay. Exp Eye Res 2013;112:51-56
34. Monti M, Donnini S, Morbidelli L, et al. PKĆ activation promotes FGF-2 exocytosis and induces endothelial cell proliferation and sprouting. J Mol Cell Cardiol 2013;63:107-117
35. Dal Monte M, Ristori C, Cammalleri M, Bagnoli P. Effects of somatostatin analogues on retinal angiogenesis in a mouse model of oxygen-induced retinopathy: Involvement of the somatostatin receptor subtype 2. Invest Ophthalmol Vis Sci 2009;50:3596-3606
36. Dal Monte M, Casini G, la Marca G, Isacchi B, Filippi L, Bagnoli P. Eye drop propranolol administration promotes the recovery of oxygen-induced retinopathy in mice. Exp Eye Res 2013;111:27-35
37. Zilberberg L, Shinkaruk S, Lequin O, et al. Structure and inhibitory effects on angiogenesis and tumor development of a new vascular endothelial growth inhibitor. J Biol Chem 2003;278:35564-35573
38. Pisano C, Aulicino C, Vesci L, et al. Undersulfated, low-molecular-weight glycol-split heparin as an antiangiogenic VEGF antagonist. Glycobiology 2005;15: 1C-6C
39. Mitola S, Ravelli C, Moroni E, et al. Gremlin is a novel agonist of the major proangiogenic receptor VEGFR2. Blood 2010;116:3677-3680
40. Ziche M, Morbidelli L. The corneal pocket assay. Methods Mol Biol 2009; 467:319-329
41. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 2003;22:1-29
42. Collino M, Pini A, Mastroianni R, et al. The non-anticoagulant heparin-like K5 polysaccharide derivative K5-N,OSepi attenuates myocardial ischaemia/reperfusion injury [published correction appears in J Cell Mol Med 2013;17:1652]. J Cell Mol Med 2012;16:2196-2207
43. Collino M, Castiglia S, Manoni M, et al. Effects of a semi-synthetic N-,Osulfated glycosaminoglycan K5 polysaccharide derivative in a rat model of cerebral ischaemia/reperfusion injury. Thromb Haemost 2009;102:837-845
44. Gori AM, Attanasio M, Gazzini A, et al. Cytokine gene expression and production by human LPS-stimulated mononuclear cells are inhibited by sulfated heparin-like semi-synthetic derivatives. J Thromb Haemost 2004;2:1657-1662
45. Watanabe D, Suzuma K, Matsui S, et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med 2005;353:782-792
46. Yang J, Klassen H, Pries M, Wang W, Nissen MH. Vitreous humor and albumin augment the proliferation of cultured retinal precursor cells. J Neurosci Res 2009;87:495-502
47. Scott A, Fruttiger M. Oxygen-induced retinopathy: A model for vascular pathology in the retina. Eye (Lond) 2010;24:416-421
48. Remtulla S, Hallett PE. A schematic eye for the mouse, and comparisons with the rat. Vision Res 1985;25:21-31